OTCMKTS:RSLS

ReShape Lifesciences Stock Forecast, Price & News

$4.20
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.20
Now: $4.20
$4.20
50-Day Range
$4.10
MA: $4.82
$6.50
52-Week Range
$1.14
Now: $4.20
$14.00
Volume10 shs
Average Volume3,018 shs
Market Capitalization$25.90 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
ReShape Lifesciences logo

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolOTCMKTS:RSLS
CUSIP29365M20
Phone949-429-6680
Employees37
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.09 million
Book Value$61.65 per share

Profitability

Net Income$-74,210,000.00
Net Margins-314.18%

Miscellaneous

Market Cap$25.90 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

Headlines

These Small Caps Are Ripping On Merger Announcement
January 20, 2021 |  baystreet.ca
See More Headlines

MarketRank

Overall MarketRank

0.63 out of 5 stars

Medical Sector

1343rd out of 2,024 stocks

Electromedical Equipment Industry

36th out of 61 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$4.20
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RSLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ReShape Lifesciences (OTCMKTS:RSLS) Frequently Asked Questions

Is ReShape Lifesciences a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ReShape Lifesciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ReShape Lifesciences stock.
View analyst ratings for ReShape Lifesciences
or view top-rated stocks.

What stocks does MarketBeat like better than ReShape Lifesciences?

Wall Street analysts have given ReShape Lifesciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ReShape Lifesciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ReShape Lifesciences' next earnings date?

ReShape Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for ReShape Lifesciences
.

How were ReShape Lifesciences' earnings last quarter?

ReShape Lifesciences Inc. (OTCMKTS:RSLS) issued its quarterly earnings data on Wednesday, March, 10th. The medical device company reported ($1.23) earnings per share for the quarter. The medical device company had revenue of $3.21 million for the quarter. ReShape Lifesciences had a negative trailing twelve-month return on equity of 186.31% and a negative net margin of 314.18%.
View ReShape Lifesciences' earnings history
.

How has ReShape Lifesciences' stock been impacted by COVID-19?

ReShape Lifesciences' stock was trading at $5.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RSLS shares have decreased by 24.3% and is now trading at $4.20.
View which stocks have been most impacted by COVID-19
.

When did ReShape Lifesciences' stock split? How did ReShape Lifesciences' stock split work?

ReShape Lifesciences shares reverse split on the morning of Thursday, November 8th 2018. The 1-140 reverse split was announced on Wednesday, November 7th 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 7th 2018. An investor that had 100 shares of ReShape Lifesciences stock prior to the reverse split would have 1 shares after the split.

Who are ReShape Lifesciences' key executives?

ReShape Lifesciences' management team includes the following people:
  • Mr. Barton P. Bandy, Pres, CEO & Director (Age 58, Pay $377k)
  • Mr. Thomas Stankovich, Sr. VP of Fin. & CFO (Age 60, Pay $290k)
  • Dr. Mark B. Knudson Ph.D., Co-Founder and Special Advisor to the CEO (Age 72)
  • Dr. Katherine S. Tweden, Co-Founder (Age 60)
  • Mr. Vipul Shah, Sr. VP of Operations and R&D
  • Dr. Rajesh Nihalani, Chief Technology Officer & Bus. Devel. (Age 51)
  • Dr. Dov Gal, VP of Regulatory & Clinical Affairs and Compliance Officer
  • Jody B. Dahlman, Director of Communications
  • Mr. Kevin Condrin, Sr. VP of Commercial
  • Mr. Brendan O'Connell, VP of Fin. & Corp. Controller (Age 44)

Who are some of ReShape Lifesciences' key competitors?

What other stocks do shareholders of ReShape Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReShape Lifesciences investors own include XOMA (xoma), CTI BioPharma (CTIC), Synergy Pharmaceuticals (SGYP), DryShips (DRYS), La Jolla Pharmaceutical (LJPC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Neovasc (NVCN), Clovis Oncology (CLVS) and CytRx (CYTR).

What is ReShape Lifesciences' stock symbol?

ReShape Lifesciences trades on the OTCMKTS under the ticker symbol "RSLS."

How do I buy shares of ReShape Lifesciences?

Shares of RSLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ReShape Lifesciences' stock price today?

One share of RSLS stock can currently be purchased for approximately $4.20.

How much money does ReShape Lifesciences make?

ReShape Lifesciences has a market capitalization of $25.90 million and generates $15.09 million in revenue each year.

How many employees does ReShape Lifesciences have?

ReShape Lifesciences employs 37 workers across the globe.

What is ReShape Lifesciences' official website?

The official website for ReShape Lifesciences is www.reshapelifesciences.com.

Where are ReShape Lifesciences' headquarters?

ReShape Lifesciences is headquartered at 1001 Calle Amanecer, San Clemente CA, 92673.

How can I contact ReShape Lifesciences?

ReShape Lifesciences' mailing address is 1001 Calle Amanecer, San Clemente CA, 92673. The medical device company can be reached via phone at 949-429-6680 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.